Clinical trials
catalyst calendar across sponsors →Studies where NSPR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 2 observational
Held by 5 tracked-famous managers (MARSHALL WACE, LLP, RENAISSANCE TECHNOLOGIES LLC, Schonfeld Strategic Advisors LLC, MILLENNIUM MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 2.5 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| CGUARDIANS III IDE Pivotal TrialNCT07277296Composite primary endpointOpen-label · Treatment | Not applicable | Not yet recruiting | Device: SwitchGuardTM NPS | Carotid Artery Stenosis | 103 | 2027-02-01 | in 165 d | 2025-12-11 |
| A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization ApproachNCT06653387Acute device successOpen-label · Treatment | Not applicable | Recruiting | Device: CGuard Prime 80cm stent system | Carotid Artery Diseases | 50 | 2026-11-20 | in 92 d | 2025-05-31 |
| Safety and Efficacy of the CGuard™ Carotid Stent System in Carotid Artery StentingNCT04900844Composite of DSMI through 30 days or ipsilateral stroke 31 - 365 days post-index procedureOpen-label · Treatment | Not applicable | Active, not recruiting | Device: CGuard Carotid Stent implantation | Carotid Artery Stenosis | 317 | 2022-07-01actual | — | 2025-04-04 |
| OCT Study of the MGuard Prime Stent in Patients With Heart AttacksNCT02222116The primary endpoint is the minFA as measured by OCT at end of primary PCI (after stent deployment but before postdilatation), powered to demonstrate superiority of the MGuard Prime stent compared to the control arm.Randomized · Open-label · Treatment | Phase 4 | Withdrawnsponsor's stated reason: Market move to DES | Device: MGuard Prime, Control BMS DES | ST Segment Elevated Myocardial Infarction | 0 | Nov 2015 | — | 2015-03-31 |
| MGuard™ Prime Embolic Protection Stent in Patients With Acute ST Elevation Myocardial InfarctionNCT02292823observationalComplete ST-segment resolution | — | Terminatedsponsor's stated reason: Enrolment rate | Device: MGuard™ Prime Embolic Protection Stent System | ST Elevation Myocardial Infarction | 63 | Sep 2015 | — | 2015-09-02 |
| MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial InfarctionNCT01869738rate of complete ST-segment resolution within 60-90 minutesRandomized · Single-masked · Treatment | Not applicable | Terminatedsponsor's stated reason: low enrollment rate | Device: MGuard Prime, (BMS/DES) | ST Elevation Myocardial Infarction | 310 | Aug 2015actual | — | 2015-09-02 |
| The Israeli MGuard RegistryNCT00922337observationalMajor Cardiac Adverse Events rate (MACE) | — | Completed | Device: MGuard Coronary Stent system | Ischemic Heart Disease, Acute Coronary Syndrome, Acute Myocardial Infarction | 86 | Jun 2013actual | — | 2014-03-06 |
| Safety and Efficacy Study of MGuard Stent After a Heart AttackNCT01368471The incidence of complete ST segment resolution (defined as ≥70% ST 1. The incidence of complete ST segment resolutionRandomized · Single-masked · Treatment | Phase 4 | Completed | Device: MGuard, Control BMS or DES | Myocardial Infarction | 433 | Jun 2012actual | — | 2013-05-29 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19